All In Biotech

Free tool

FAERS Monitor: Fabhalta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218276 or its brand name (Fabhalta, Iptacopan Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

800

Serious

392

49% of reports

Hospitalization

193

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache89
  • fatigue62
  • haemoglobin decreased56
  • pyrexia56
  • nausea49
  • diarrhoea44
  • drug ineffective44
  • product dose omission issue39
  • breakthrough haemolysis37
  • off label use35
  • pneumonia34
  • rash32
  • vomiting32
  • asthenia29
  • dizziness29

Reports by year received

View as table
YearReports
20221
20236
2024259
2025327
2026207

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,359 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breakthrough haemolysisSignal372689.81931.687,806
haemoglobin decreasedSignal5614.311.1685
pyrexiaSignal564.33.3138
headacheSignal893.73.1181
product dose omission issueSignal393.52.668
pneumoniaSignal342.82.037
fatigueSignal622.11.636
astheniaSignal292.01.414
rash321.91.414
diarrhoea441.81.315
vomiting321.81.311
nausea491.61.212
dizziness291.51.15
off label use351.10.80
drug ineffective440.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.